Acute Heart Failure - COngestion Discharge Evaluation

Condition(s) studied

Investigational drug(s) / intervention(s)

Clinical examination centered on congestion: Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital

Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital

Blood sample retrieved for biological assessment and biobanking: Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital

Telephone follow-up: Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital

Kansas City Cardiomyopathy Questionnaire (KCCQ): Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge

Study summary

Acute heart failure (AHF) is a major public health problem, associated with a 40% risk of death or re-hospitalisation at 3 months. This risk is significantly increased by insufficient decongestion at the end of hospitalisation for AHF assessed by a standardised clinical score, a natriuretic peptide dosage or by cardiac and pulmonary ultrasound .

Adapting treatment according to lung congestion assessed by implantable devices (not reimbursed in France) improves the prognosis. However, due to the lack of a standardised congestion assessment, therapeutic adaptation in acute heart failure is currently empirical. The best multimodality approach to congestion evaluation is uncertain.

Eligibility

Primary outcome measure(s)

• Rate of all-cause death — 3 months after hospital discharge
  composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 2 and 3)
• Rate of re-hospitalisation for acute heart failure — 3 months after hospital discharge
  composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 1 and 3)
• Rate of day-hospital or in-home IV diuretics injection for acute HF — 3 months after hospital discharge
  composite endpoint: rate of all-cause death, hospitalization for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 1 and 2)

Trial sites (1)

More Central Hospital, Nancy, France trials in France

Other trials for the same condition